TG
RLAY icon

TCW Group’s Relay Therapeutics RLAY Stock Holding History

TCW Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-80,943
Closed -$2.96M – 350
2021
Q2 		$2.96M Sell
80,943
-7,185
-8% -$237K 0.03% 236
2021
Q1 		$3.05M Sell
88,128
-20,014
-19% -$869K 0.03% 231
2020
Q4 		$4.49M Sell
108,142
-33,793
-24% -$1.53M 0.04% 199
2020
Q3 		$6.04M Buy
+141,935
New +$5.41M 0.07% 158

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCW Group's RLAY Position: Q3 2021 in Review

TCW Group sold out of Relay Therapeutics (RLAY) in Q3 2021, closing a stake of 80,943 shares — an estimated $2.96M sold.

TCW Group first reported a position in RLAY in Q3 2020 and held it in 4 quarters. The position peaked at $6.04M in Q3 2020. 132 funds tracked by Wall St. Rank hold RLAY as of Q3 2021.

  • TCW Group reported no remaining Relay Therapeutics position as of Q3 2021 after selling out during the quarter.
  • TCW Group sold 80,943 Relay Therapeutics shares in Q3 2021, an estimated $2.96M.
  • TCW Group first reported a position in Relay Therapeutics in Q3 2020 and held it in 4 quarters.
  • TCW Group's Relay Therapeutics position peaked at $6.04M in Q3 2020.
  • 132 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2021.

Based on TCW Group's 13F filing for Q3 2021, filed 26 Oct 2021.